JPWO2023038030A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2023038030A5 JPWO2023038030A5 JP2023546948A JP2023546948A JPWO2023038030A5 JP WO2023038030 A5 JPWO2023038030 A5 JP WO2023038030A5 JP 2023546948 A JP2023546948 A JP 2023546948A JP 2023546948 A JP2023546948 A JP 2023546948A JP WO2023038030 A5 JPWO2023038030 A5 JP WO2023038030A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- pyrazino
- hydroxybenzyl
- hexahydro
- dioxo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 11
- 150000003839 salts Chemical class 0.000 claims 6
- 239000003369 serotonin 5-HT3 receptor antagonist Substances 0.000 claims 6
- NTHPAPBPFQJABD-LLVKDONJSA-N ramosetron Chemical compound C12=CC=CC=C2N(C)C=C1C(=O)[C@H]1CC(NC=N2)=C2CC1 NTHPAPBPFQJABD-LLVKDONJSA-N 0.000 claims 4
- 229950001588 ramosetron Drugs 0.000 claims 4
- 230000002496 gastric effect Effects 0.000 claims 3
- 208000024891 symptom Diseases 0.000 claims 3
- NTDPIIZFZPOWML-UHFFFAOYSA-N 4h-triazine-3-carboxamide Chemical compound NC(=O)N1CC=CN=N1 NTDPIIZFZPOWML-UHFFFAOYSA-N 0.000 claims 2
- 229960003727 granisetron Drugs 0.000 claims 2
- MFWNKCLOYSRHCJ-BTTYYORXSA-N granisetron Chemical compound C1=CC=C2C(C(=O)N[C@H]3C[C@H]4CCC[C@@H](C3)N4C)=NN(C)C2=C1 MFWNKCLOYSRHCJ-BTTYYORXSA-N 0.000 claims 2
- 229960003607 granisetron hydrochloride Drugs 0.000 claims 2
- QYZRTBKYBJRGJB-UHFFFAOYSA-N hydron;1-methyl-n-(9-methyl-9-azabicyclo[3.3.1]nonan-3-yl)indazole-3-carboxamide;chloride Chemical compound Cl.C1=CC=C2C(C(=O)NC3CC4CCCC(C3)N4C)=NN(C)C2=C1 QYZRTBKYBJRGJB-UHFFFAOYSA-N 0.000 claims 2
- FELGMEQIXOGIFQ-CYBMUJFWSA-N (3r)-9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1h-carbazol-4-one Chemical compound CC1=NC=CN1C[C@@H]1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 FELGMEQIXOGIFQ-CYBMUJFWSA-N 0.000 claims 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims 1
- NKZFAEJZZASIBG-UHFFFAOYSA-N 6H-1,2,4-triazine-1-carboxamide Chemical compound N1(N=CN=CC1)C(=O)N NKZFAEJZZASIBG-UHFFFAOYSA-N 0.000 claims 1
- WUKZPHOXUVCQOR-UHFFFAOYSA-N N-(1-azabicyclo[2.2.2]octan-3-yl)-6-chloro-4-methyl-3-oxo-1,4-benzoxazine-8-carboxamide Chemical compound C1N(CC2)CCC2C1NC(=O)C1=CC(Cl)=CC2=C1OCC(=O)N2C WUKZPHOXUVCQOR-UHFFFAOYSA-N 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 206010047700 Vomiting Diseases 0.000 claims 1
- 229950005951 azasetron Drugs 0.000 claims 1
- 125000004566 azetidin-1-yl group Chemical group N1(CCC1)* 0.000 claims 1
- 229950007467 indisetron Drugs 0.000 claims 1
- MHNNVDILNTUWNS-XYYAHUGASA-N indisetron Chemical compound C1=CC=C2C(C(=O)N[C@H]3C[C@H]4CN(C[C@@H](C3)N4C)C)=NNC2=C1 MHNNVDILNTUWNS-XYYAHUGASA-N 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 229960005343 ondansetron Drugs 0.000 claims 1
- 229960002131 palonosetron Drugs 0.000 claims 1
- CPZBLNMUGSZIPR-NVXWUHKLSA-N palonosetron Chemical compound C1N(CC2)CCC2[C@@H]1N1C(=O)C(C=CC=C2CCC3)=C2[C@H]3C1 CPZBLNMUGSZIPR-NVXWUHKLSA-N 0.000 claims 1
- 239000002464 receptor antagonist Substances 0.000 claims 1
- 229940044551 receptor antagonist Drugs 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021146389 | 2021-09-08 | ||
| JP2021146389 | 2021-09-08 | ||
| PCT/JP2022/033458 WO2023038030A1 (ja) | 2021-09-08 | 2022-09-06 | 固形腫瘍治療用医薬組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JPWO2023038030A1 JPWO2023038030A1 (https=) | 2023-03-16 |
| JPWO2023038030A5 true JPWO2023038030A5 (https=) | 2023-11-27 |
| JP7445826B2 JP7445826B2 (ja) | 2024-03-07 |
Family
ID=85507597
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023546948A Active JP7445826B2 (ja) | 2021-09-08 | 2022-09-06 | 固形腫瘍治療用医薬組成物 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20250222003A1 (https=) |
| EP (1) | EP4364742A4 (https=) |
| JP (1) | JP7445826B2 (https=) |
| KR (1) | KR20240056487A (https=) |
| CN (1) | CN117794544A (https=) |
| AU (1) | AU2022342537A1 (https=) |
| CA (1) | CA3227813A1 (https=) |
| MX (1) | MX2024002060A (https=) |
| WO (1) | WO2023038030A1 (https=) |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110288115A1 (en) * | 2010-05-24 | 2011-11-24 | Avmedis Llc | Treatment of vagally-mediated spectrum disorders |
| KR20160061911A (ko) * | 2013-04-08 | 2016-06-01 | 데니스 엠. 브라운 | 최적하 투여된 화학 화합물의 치료 효과 |
| CN112472699A (zh) * | 2013-07-26 | 2021-03-12 | 种族肿瘤学公司 | 改善比生群及衍生物的治疗益处的组合方法 |
| US9174998B2 (en) * | 2013-12-25 | 2015-11-03 | Eisai R&D Management Co., Ltd. | (6S,9aS)-N-benzyl-6-[(4-hydroxyphenyl)methyl]-4,7-dioxo-8-({6-[3-(piperazin-1-yl)azetidin-1-yl]pyridin-2-yl}methyl)-2-(prop-2-en-1-yl)-octahydro-1H-pyrazino[2,1-c][1,2,4]triazine-1-carboxamide compound |
| CA2986999C (en) | 2015-06-23 | 2023-08-08 | Eisai R&D Management Co., Ltd. | Crystal of (6s,9as)-n-benzyl-8-({6-[3-(4-ethylpiperazin-1-yl)azetidin-1-yl]pyridin-2-yl}methyl)-6-(2-fluoro-4-hydroxybenzyl)-4,7-dioxo-2-(prop-2-en-1-yl)hexahydro-2h-pyrazino[2,1-c][1,2,4]triazine-1(6h)-carboxamide |
| US12303505B2 (en) * | 2017-02-08 | 2025-05-20 | Eisai R&D Management Co., Ltd. | Tumor-treating pharmaceutical composition |
| EP4051278B1 (en) * | 2019-10-29 | 2025-12-17 | Eisai R&D Management Co., Ltd. | Combination of a pd-1 antagonist, a vegfr/fgfr/ret tyrosine kinase inhibitor and a cbp/beta-catenin inhibitor for treating cancer |
-
2022
- 2022-09-06 MX MX2024002060A patent/MX2024002060A/es unknown
- 2022-09-06 US US18/293,848 patent/US20250222003A1/en active Pending
- 2022-09-06 JP JP2023546948A patent/JP7445826B2/ja active Active
- 2022-09-06 CA CA3227813A patent/CA3227813A1/en active Pending
- 2022-09-06 WO PCT/JP2022/033458 patent/WO2023038030A1/ja not_active Ceased
- 2022-09-06 EP EP22867352.1A patent/EP4364742A4/en active Pending
- 2022-09-06 KR KR1020247003704A patent/KR20240056487A/ko active Pending
- 2022-09-06 CN CN202280052902.2A patent/CN117794544A/zh active Pending
- 2022-09-06 AU AU2022342537A patent/AU2022342537A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2101759B1 (en) | Methods of using mek inhibitors | |
| AU2012301953C1 (en) | Antibacterial compounds and methods for use | |
| ES2306146T3 (es) | Uso de derivados de quinolina sustituidos para el tratamiento de enfermedades micobacterianas resistentes a farmacos. | |
| JP2014518266A5 (https=) | ||
| JP2009536176A5 (https=) | ||
| JP2019503365A5 (https=) | ||
| CA2688695A1 (en) | Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione | |
| JP2009510043A5 (https=) | ||
| JP2013528204A5 (https=) | ||
| JP2002523502A5 (https=) | ||
| JP2016504392A (ja) | 抗レトロウイルス剤としての（ヘテロ）アリールアセトアミド誘導体 | |
| JP2021501145A5 (https=) | ||
| NO327581B1 (no) | Pyrimidinforbindelse, farmasoytisk preparat omfattende denne, og anvendelser av forbindelsen. | |
| JP2009525343A5 (https=) | ||
| JP2010514807A5 (https=) | ||
| KR101767859B1 (ko) | 아자 2 고리형 화합물을 사용한 암 병용 요법 | |
| RU2009122241A (ru) | Твердые формы рацемического илапразола | |
| JP2010514806A5 (https=) | ||
| JP2006516977A5 (https=) | ||
| JP2021505575A5 (https=) | ||
| JP2009506989A (ja) | アザビシクロヘキサン誘導体の使用 | |
| KR20140027939A (ko) | 지양제 | |
| JP2024516353A5 (https=) | ||
| JP2017534654A5 (https=) | ||
| JP2009517411A5 (https=) |